Improved Insulin Sensitivity with Sodium-Glucose Cotransporter 2 Inhibitor Treatment in a Patient with Slowly Progressive Type 1 Diabetes Mellitus with Metabolic Syndrome: a Case Report
Diabetology International(2020)
Abstract
We herein report the clinical course of a 56-year-old Japanese patient with slowly progressive type 1 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease, and severe insulin resistance. The patient’s intravenous glucose tolerance test indicated marked reductions in insulin sensitivity and endogenous insulin secretion. Accordingly, administration of ipragliflozin l -proline, a sodium-glucose cotransporter 2 inhibitor, promoted improvements in insulin sensitivity and blood glucose levels, as well as a decrease in visceral fat, improvement in dyslipidemia, and decrease in hepatic lipid content, suggesting the potential efficacy of sodium-glucose cotransporter 2 inhibitors for obese patients with type 1 diabetes mellitus exhibiting insulin resistance.
MoreTranslated text
Key words
Slowly progressive type 1 diabetes mellitus,Insulin resistance,Metabolic syndrome,Non-alcoholic fatty liver disease,Sodium-glucose cotransporter 2 inhibitor
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined